News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

The Three Most Important Drugs in Gilead (GILD)'s Pipeline



12/7/2015 7:01:10 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Although blue-chip biotech stock Gilead Sciences (NASDAQ:GILD) has had a bit of an up and down year, it's still sitting on a year-to-date gain of nearly 10%.

The catalyst behind Gilead's ongoing strength has been its hepatitis C franchise, headlined by Sovaldi and Harvoni, the company's once-daily HCV pills. These drugs have made an incredible difference in the lives of HCV patients, with cure rates typically above 90%, and relatively minimal side effects compared to the flu-like symptoms, anemia, and rashes which often accompanied the previous standard of care.

Read at Motley Fool


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES